Overview

• The Nature Medicine publication reports a randomized, placebo-controlled trial of about 820 adults in Germany and Austria that met its primary endpoint for pain reduction.
• Participants taking VER-01 saw an average 1.9-point drop on a 0–10 pain scale versus 1.4 points with placebo, with greater benefits in those with a neuropathic pain component.
• VER-01 users also reported better sleep and physical function, and longer follow-up showed continued pain reduction without signs of dose escalation.
• Adverse events were mostly mild to moderate, with 17.3% discontinuing due to side effects versus 3.5% on placebo, and investigators found no evidence of abuse, dependence, or withdrawal.
• Vertanical has filed for European approval and says it is working with U.S. regulators to design a study that could support an FDA submission, reflecting the drug’s standardized 2.5 mg THC per-dose formulation.